Clinical Trials
2 trialsNCT02564198 2021-08-17
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT00895180 2017-12-27
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed